# Zylox-Tonbridge and GL Capital to Invest HK$1.482 Billion in LifeTech Scientific

> Zylox-Tonbridge and GL Capital will invest about HK$1.482 billion in LifeTech Scientific through Lighthouse Two.

- Published: 2026-11-06T18:03:59+00:00
- Section: Funding
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-06/zylox-tonbridge-gl-capital-lifetech-investment
- Source: [PR Newswire](https://www.prnewswire.com/news-releases/zylox-tonbridge-and-gl-capital-announce-strategic-investment-in-lifetech-scientific-to-build-a-leading-vascular-and-structural-heart-intervention-platform-302932244.html)

## Key takeaways

- Zylox-Tonbridge and GL Capital will jointly invest approximately HK$1.482 billion in LifeTech Scientific through GL Lighthouse Two Investment Limited.
- Zylox-Tonbridge will hold a 60% stake in Lighthouse Two through an investment of approximately HK$889 million.
- GL Capital will subscribe for 39.8 million new Zylox-Tonbridge shares at HK$22 per share, about 10.8% of the enlarged issued share capital.

Zylox-Tonbridge Medical Technology and GL Capital will jointly invest approximately HK$1.482 billion in LifeTech Scientific Corporation through GL Lighthouse Two Investment Limited, which will subscribe for newly issued shares representing approximately 16.7% of LifeTech's enlarged share capital, [PR Newswire](https://www.prnewswire.com/news-releases/zylox-tonbridge-and-gl-capital-announce-strategic-investment-in-lifetech-scientific-to-build-a-leading-vascular-and-structural-heart-intervention-platform-302932244.html) reported on November 6, 2026.

## How the Lighthouse Two Investment Is Structured

[Zylox-Tonbridge](https://akta.pro/company-profiles/00kin7j/zylox-tonbridge) will hold a 60% stake in Lighthouse Two through an investment of approximately HK$889 million. Upon completion, Lighthouse Two will become [LifeTech](https://akta.pro/company-profiles/0037aa5/lifetech-scientific-co-ltd)'s largest single shareholder.

In a related transaction, [GL Capital](https://akta.pro/company-profiles/0000n48/gl-capital) will subscribe for 39.8 million newly issued Zylox-Tonbridge shares at HK$22 per share, representing approximately 10.8% of the company's enlarged issued share capital. The subscription price represents a 13.5% premium to the closing share price on the announcement date and a 15.4% premium to the average closing price over the preceding five trading days.

The proceeds will support Zylox-Tonbridge's potential future investments in LifeTech and international business development. Zylox-Tonbridge and GL Capital may acquire additional shares in LifeTech, and Zylox-Tonbridge intends to pursue a potential merger with LifeTech.

Dr. Jonathon Zhong Zhao, Chairman of Zylox-Tonbridge, said: "This strategic investment marks an important milestone in our ambition to build a leading integrated vascular and structural heart intervention platform in China."

LifeTech terminated a framework agreement on November 5, 2026, concerning the proposed acquisition of Starway equity and other matters, The future of trading reported.

## Zylox-Tonbridge's Revenue and Profit Growth

According to akta.pro [company records](https://akta.pro/company-data), Zylox-Tonbridge reported full-year 2025 revenue of RMB 1.06 billion, up 35.1% year over year, and net profit of RMB 244 million, up 143.7% year over year. Non-IFRS adjusted net profit was RMB 273 million. International revenue surged 115.5% to RMB 48.65 million.

The same records show Zylox-Tonbridge entered into a definitive agreement in January 2026 to acquire Germany-based Optimed Medizinische Instrumente GmbH, a specialist in minimally invasive vascular and endourology devices founded in 1996 and based in Ettlingen, Germany.

| Figure | Value |
| --- | --- |
| Full-year 2025 revenue | RMB 1.06 billion, up 35.1% year over year |
| 2025 net profit | RMB 244 million, up 143.7% year over year |
| Non-IFRS adjusted net profit | RMB 273 million |
| International revenue | RMB 48.65 million, up 115.5% year over year |

## LifeTech's Interim Results

LifeTech Scientific Corporation reported unaudited interim results for the six months ended June 30, 2026, with revenue of about RMB600.8 million and a gross profit margin of 77.5%, up 3.9 percentage points, Aijourn reported.

## Companies in this story

- [Zylox-Tonbridge company profile](https://akta.pro/company-profiles/00kin7j/zylox-tonbridge) · website: https://www.zyloxtb.com
- [Lifetech Scientific Co, Ltd company profile](https://akta.pro/company-profiles/0037aa5/lifetech-scientific-co-ltd) · website: http://www.lifetechmed.com
- [GL Capital company profile](https://akta.pro/company-profiles/0000n48/gl-capital) · website: https://www.gl-investment.com

---
News for Agent · https://newsforagent.com/llms.txt